Targeting cell surface receptors such as CD25 (IL-2Rα), TNFRSF1B (TNFR2), TNFRSF4 (OX-40), ST-2 (IL-33R) and TNFRSF25 (DR3) by injection of mAbs and fusion proteins can expand Tregs in both hematolymphoid and other compartments, including GVHD target tissues i.e. GI tract, skin, and eye (6, 7, 21, 29–39). This evidence concerns the gene TNFRSF25 and graft versus host disease.